GeoVax Labs (NASDAQ:GOVX) Receives “Buy” Rating from D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock.

Other equities analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Friday, November 15th. Alliance Global Partners initiated coverage on GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Stock Performance

GOVX opened at $2.25 on Thursday. The company’s 50-day simple moving average is $2.46 and its two-hundred day simple moving average is $2.81. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same quarter last year, the company earned ($4.80) EPS. On average, sell-side analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs as of its most recent SEC filing. 6.09% of the stock is owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.